Diffusion tensor imaging correlates of memory and language impairments in temporal lobe epilepsy

TLDR

Drug‑resistant malaria strains and limited understanding of chloroquine resistance highlight the urgent need for new antimalarial drugs. The study reviews gaps in knowledge about antimalarial mechanisms and summarizes current prophylaxis and therapy recommendations for drug‑resistant malaria. The authors propose using combination therapies and large‑scale drug discovery to address antimalarial resistance. Screening of over 250,000 compounds has identified several promising candidates now in clinical trials for multi‑drug‑resistant falciparum malaria.

Abstract

New antimalarial drugs are required, partly because of the emergence of drug resistant strains of malaria parasites and partly because better compounds are needed to cure relapsing tertian malaria. In reviewing the diverse modes of action of currently used anti-malarials, against a background of the pathogenesis of malaria, attention is drawn to deficiencies in our knowledge. Even less do we understand how the malaria parasite becomes resistant to certain drugs, in particular chloroquine. New approaches to the problem include the application of combinations of existing antimalarials, and the search for new drugs on an unprecedentedly vast scale. Out of over a quarter million compounds that have recently been screened, a handful are now in clinical trial and are showing great promise for the treatment of multiple resistant falciparum malaria. The paper concludes by summarizing current recommendations for the prophylaxis and therapy of malaria due to drug resistant parasites.